Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2024 | Update from the X-TOLE open label extension study of XEN1101 in focal epilepsy

Jacqueline French, MD, NYU Comprehensive Epilepsy Center, New York, NY, shares interim safety and efficacy data from the ongoing open-label extension (OLE) study on XEN1101 in adults with focal epilepsy. XEN1101, a potent, selective potassium channel opener, was studied in the Phase IIb X-TOLE study, where it was shown to induce a statistically significant reduction in seizure frequency in a dose-dependent manner. At 18-months of follow up in the OLE, over 50% of patients from the original study continue to receive the drug. Median percentage change in monthly focal onset seizure frequency was -83.4% at 18 months compared to baseline. Adverse events were mostly mild or moderate, with only 2.2% patients experiencing treatment-related serious adverse events. The ongoing X-TOLE2/X-TOLE3 Phase III studies are testing XEN1101 as an adjunctive treatment in adults with focal onset seizures on 1-3 antiseizure medications, while X-ACKT will test XEN1101 in patients with primary generalized tonic-clonic seizures. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.